Backs 2022 non-GAAP net loss view of under $275M. "Our strong year-to-date results, including year-over-year revenue growth of nearly 20%, keep us on track to meet our 2022 P&L guidance," said CFO Elizabeth Hougen. "Additionally, we recently bolstered our balance sheet when we unlocked net proceeds of approximately $240M plus full funding to expand our R&D campus by capitalizing on the favorable life sciences real estate market and monetizing several of our facilities through a sale and leaseback transaction. As a result, we are increasing our 2022 cash and short-term investment guidance to approximately $2B."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IONS:
